Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non-muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort

TheScientificWorldJournal

Volumn 11, Issue , 2011, Pages 751-759

  Pillai, Rajiv ^a   Wang, Duolao ^b   Mayer, Erik K ^c   Abel, Paul ^d  

^a WEST SUFFOLK HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

EORTC risk tables; Progression; pTa pT1 bladder cancer; Recurrence

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CALCULATOR; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OUTCOME ASSESSMENT; PREDICTION; PROBABILITY; PROGNOSIS; STATISTICAL MODEL; TRANSITIONAL CELL CARCINOMA; VALIDITY;

ALGORITHMS; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; PROGNOSIS; RECURRENCE; URINARY BLADDER NEOPLASMS;

EID: 79955663459     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2011.77     Document Type: Article

References (18)

1. Millan-Rodriguez, F., Chechile-Toniolo, G., Salvador-Bayarri, J., Palou, J., and Vincente-Rodriguez, J. (2000) Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol. 163, 73-78.
2. Kwak, C., Ku, J.H., Park, J.Y., Lee, E., Lee, S.E., and Lee, C. (2004) Initial tumour stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer. J. Urol. 171, 149-152. (Pubitemid 37549111)
3. Shariat, S., Casella, R., Monoski, M., Sulser, T., Gasser, T., and Lerner, S. (2003) The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J. Urol. 170, 2244-47. (Pubitemid 37413968)
4. Shariat, S., Casella, R., Wians, F.H., Jr., Ashfaq, R., Balko, J., Sulser, T., Gasser, T., and Salgowsky, A. (2004) Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur. Urol. 45, 304-313. (Pubitemid 38221403)
5. Abel, P.D. (1988) Prognostic indices in transitional cell carcinoma of the bladder. Br. J. Urol. 62, 103-109.
6. Sylvester, R., Van der Mejiden, A., Oosterlinck, W., Witjes, J., Bouffioux, C., Denis, L., Newling, D., and Kurth, K. (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466-477.
7. Abel, P.D., Hall, R.R., and Williams, G. (1988) Should pT1 transitional cell cancers of the bladder still be classified as superficial? Br. J. Urol. 62, 235-239.
8. Kaplan, E.L. and Meier, P. (1958) Non-parametric estimation from incomplete observations. J. Am. Statist. Assoc. 53, 457-481.
9. Harrell, F.E., Lee, K.L., and Mark, D.B. (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statist. Med. 15, 361-387. (Pubitemid 26072233)
10. Oosterlinck, W., Lobel, B., Jakse, G., Malmstrom, P., Stockle, M., and Strenberg, C. (2002) Guidelines on bladder cancer. Eur. Urol. 41, 105-112. (Pubitemid 35428874)
11. Shariat, S., Zippe, C., Ludecke, G., Boman, H., Sanchez-Carbayo, M., Casella, R., Mian, C., Friedrich, M., Eissa, S., Akaza, H., Sawczuk, I., Serretta, V., Huland, H., Hedelin, H., Rupesh, R., Miyanaga, N., Sagalowsky, A., Wians, F., Jr., Roehrborn, C., Lotan, Y., Perrotte, P., Benayoun, S., Marberger, M., and Karakiewicz, P. (2005) Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J. Urol. 173, 1518-1525. (Pubitemid 40524761)
12. Bostwick, D.G. and Burke, H.B. (2001) Prediction of individual patient outcome in cancer: comparison of artificial neural networks and Kaplan-Meier methods. Cancer 91, 1643-1646. (Pubitemid 32319241)
13. Solsona, E., Iborra, I., Ricos, J., Monros, J., Casanova, J., and Dumont, R. (1999) Effectiveness of a single immediate mitomycin c instillation in patients with low risk superficial bladder cancer: short and long term follow up. J. Urol. 161, 1120-1123. (Pubitemid 29426099)
14. Sylvester, R., Van der meijden, A., and Lamm, D. (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168, 1964-1970.
15. Hudson, M.A. and Herr, H.W. (1995) Carcinoma in situ of the bladder. J. Urol. 153, 564-572.
16. Abel, P.D., Henderson, D., Bennett, M.K., Hall, R.R., and Williams, G. (1988) Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br. J. Urol. 62, 339-342.
17. Andius, P. and Holmang, S. (2004) Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int. 93, 980-984. (Pubitemid 38758618)
18. Yang, T.B., Zeng, F.H., and Sun, Z.O. (2006) Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study. Chin. Med. J. 119, 1821-1828.